236 related articles for article (PubMed ID: 19724022)
1. Fetal liver X receptor activation acutely induces lipogenesis but does not affect plasma lipid response to a high-fat diet in adult mice.
van Straten EM; van Meer H; Huijkman NC; van Dijk TH; Baller JF; Verkade HJ; Kuipers F; Plösch T
Am J Physiol Endocrinol Metab; 2009 Nov; 297(5):E1171-8. PubMed ID: 19724022
[TBL] [Abstract][Full Text] [Related]
2. A systems biology approach to the hepatic role of the oxysterol receptor LXR in the regulation of lipogenesis highlights a cross-talk with PPARα.
Ducheix S; Podechard N; Lasserre F; Polizzi A; Pommier A; Murzilli S; Di Lisio C; D'Amore S; Bertrand-Michel J; Montagner A; Pineau T; Loiseau N; Lobaccaro JM; Martin PG; Guillou H
Biochimie; 2013 Mar; 95(3):556-67. PubMed ID: 23063693
[TBL] [Abstract][Full Text] [Related]
3. Pharmacological activation of LXR in utero directly influences ABC transporter expression and function in mice but does not affect adult cholesterol metabolism.
van Straten EM; Huijkman NC; Baller JF; Kuipers F; Plösch T
Am J Physiol Endocrinol Metab; 2008 Dec; 295(6):E1341-8. PubMed ID: 18840761
[TBL] [Abstract][Full Text] [Related]
4. Changes in LXR signaling influence early-pregnancy lipogenesis and protect against dysregulated fetoplacental lipid homeostasis.
Nikolova V; Papacleovoulou G; Bellafante E; Borges Manna L; Jansen E; Baron S; Abu-Hayyeh S; Parker M; Williamson C
Am J Physiol Endocrinol Metab; 2017 Oct; 313(4):E463-E472. PubMed ID: 28420650
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of ERK1/2 and activation of LXR synergistically reduce atherosclerotic lesions in ApoE-deficient mice.
Chen Y; Duan Y; Yang X; Sun L; Liu M; Wang Q; Ma X; Zhang W; Li X; Hu W; Miao RQ; Xiang R; Hajjar DP; Han J
Arterioscler Thromb Vasc Biol; 2015 Apr; 35(4):948-59. PubMed ID: 25810299
[TBL] [Abstract][Full Text] [Related]
6. Concurrent activation of liver X receptor and peroxisome proliferator-activated receptor alpha exacerbates hepatic steatosis in high fat diet-induced obese mice.
Gao M; Bu L; Ma Y; Liu D
PLoS One; 2013; 8(6):e65641. PubMed ID: 23762402
[TBL] [Abstract][Full Text] [Related]
7. Ursodeoxycholic acid inhibits liver X receptor α-mediated hepatic lipogenesis via induction of the nuclear corepressor SMILE.
Lee JM; Gang GT; Kim DK; Kim YD; Koo SH; Lee CH; Choi HS
J Biol Chem; 2014 Jan; 289(2):1079-91. PubMed ID: 24265317
[TBL] [Abstract][Full Text] [Related]
8. Insulin-sensitizing effect of LXR agonist T0901317 in high-fat fed rats is associated with restored muscle GLUT4 expression and insulin-stimulated AS160 phosphorylation.
Baranowski M; Zabielski P; Błachnio-Zabielska AU; Harasim E; Chabowski A; Górski J
Cell Physiol Biochem; 2014; 33(4):1047-57. PubMed ID: 24732673
[TBL] [Abstract][Full Text] [Related]
9. A systems biology approach reveals the physiological origin of hepatic steatosis induced by liver X receptor activation.
Hijmans BS; Tiemann CA; Grefhorst A; Boesjes M; van Dijk TH; Tietge UJ; Kuipers F; van Riel NA; Groen AK; Oosterveer MH
FASEB J; 2015 Apr; 29(4):1153-64. PubMed ID: 25477282
[TBL] [Abstract][Full Text] [Related]
10. n-3 fatty acids ameliorate hepatic steatosis and dysfunction after LXR agonist ingestion in mice.
Jung UJ; Millman PN; Tall AR; Deckelbaum RJ
Biochim Biophys Acta; 2011 Sep; 1811(9):491-7. PubMed ID: 21704188
[TBL] [Abstract][Full Text] [Related]
11. Synthetic LXR agonist inhibits the development of atherosclerosis in New Zealand White rabbits.
Honzumi S; Shima A; Hiroshima A; Koieyama T; Terasaka N
Biochim Biophys Acta; 2011 Dec; 1811(12):1136-45. PubMed ID: 21875689
[TBL] [Abstract][Full Text] [Related]
12. Thyroid hormone-responsive SPOT 14 homolog promotes hepatic lipogenesis, and its expression is regulated by liver X receptor α through a sterol regulatory element-binding protein 1c-dependent mechanism in mice.
Wu J; Wang C; Li S; Li S; Wang W; Li J; Chi Y; Yang H; Kong X; Zhou Y; Dong C; Wang F; Xu G; Yang J; Gustafsson JÅ; Guan Y
Hepatology; 2013 Aug; 58(2):617-28. PubMed ID: 23348573
[TBL] [Abstract][Full Text] [Related]
13. Liver X receptor agonist methyl-3β-hydroxy-5α,6α-epoxycholanate attenuates atherosclerosis in apolipoprotein E knockout mice without increasing plasma triglyceride.
Yan W; Zhang T; Cheng J; Zhou X; Qu X; Hu H
Pharmacology; 2010; 86(5-6):306-12. PubMed ID: 21071998
[TBL] [Abstract][Full Text] [Related]
14. Activation of liver X receptors attenuates endotoxin-induced liver injury in mice with nonalcoholic fatty liver disease.
Liu Y; Han X; Bian Z; Peng Y; You Z; Wang Q; Chen X; Qiu D; Ma X
Dig Dis Sci; 2012 Feb; 57(2):390-8. PubMed ID: 21948338
[TBL] [Abstract][Full Text] [Related]
15. Resveratrol suppresses T0901317-induced hepatic fat accumulation in mice.
Gao M; Liu D
AAPS J; 2013 Jul; 15(3):744-52. PubMed ID: 23591747
[TBL] [Abstract][Full Text] [Related]
16. Liver X receptor agonist T0901317 enhanced peroxisome proliferator-activated receptor-delta expression and fatty acid oxidation in rat skeletal muscle.
Baranowski M; Blachnio-Zabielska AU; Zabielski P; Harasim E; Harasiuk D; Chabowski A; Gorski J
J Physiol Pharmacol; 2013 Jun; 64(3):289-97. PubMed ID: 23959725
[TBL] [Abstract][Full Text] [Related]
17. Nrf2 inhibits LXRα-dependent hepatic lipogenesis by competing with FXR for acetylase binding.
Kay HY; Kim WD; Hwang SJ; Choi HS; Gilroy RK; Wan YJ; Kim SG
Antioxid Redox Signal; 2011 Oct; 15(8):2135-46. PubMed ID: 21504366
[TBL] [Abstract][Full Text] [Related]
18. CCAAT/enhancer binding protein β deletion increases mitochondrial function and protects mice from LXR-induced hepatic steatosis.
Rahman SM; Choudhury M; Janssen RC; Baquero KC; Miyazaki M; Friedman JE
Biochem Biophys Res Commun; 2013 Jan; 430(1):336-9. PubMed ID: 23159614
[TBL] [Abstract][Full Text] [Related]
19. Regulation of insulin resistance and adiponectin signaling in adipose tissue by liver X receptor activation highlights a cross-talk with PPARγ.
Zheng F; Zhang S; Lu W; Wu F; Yin X; Yu D; Pan Q; Li H
PLoS One; 2014; 9(6):e101269. PubMed ID: 24972069
[TBL] [Abstract][Full Text] [Related]
20. Liver X receptor agonists augment human islet function through activation of anaplerotic pathways and glycerolipid/free fatty acid cycling.
Ogihara T; Chuang JC; Vestermark GL; Garmey JC; Ketchum RJ; Huang X; Brayman KL; Thorner MO; Repa JJ; Mirmira RG; Evans-Molina C
J Biol Chem; 2010 Feb; 285(8):5392-404. PubMed ID: 20007976
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
